Quest Diagnostics signs definitive agreement to sell HemoCue business for $300 million

Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has signed a definitive agreement to sell its HemoCue diagnostic products business to Radiometer Medical ApS for a purchase price of approximately $300 million plus customary adjustments for cash balances. HemoCue develops, produces and markets hemoglobin, glucose and other point-of-care testing systems worldwide.

"The HemoCue divestiture, along with our sale of OralDNA in December 2012, demonstrates our commitment to refocus our business on diagnostic information services," said Steve Rusckowski , President and Chief Executive Officer of Quest Diagnostics. "We plan to use the proceeds to repurchase approximately $300 million of Quest Diagnostics shares as part of our stock buyback program."

The transaction is expected to be completed in March 2013, subject to customary closing conditions.

Source:

Quest Diagnostics

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Quest Diagnostics. (2019, June 20). Quest Diagnostics signs definitive agreement to sell HemoCue business for $300 million. News-Medical. Retrieved on November 24, 2020 from https://www.news-medical.net/news/20130225/Quest-Diagnostics-signs-definitive-agreement-to-sell-HemoCue-business-for-24300-million.aspx.

  • MLA

    Quest Diagnostics. "Quest Diagnostics signs definitive agreement to sell HemoCue business for $300 million". News-Medical. 24 November 2020. <https://www.news-medical.net/news/20130225/Quest-Diagnostics-signs-definitive-agreement-to-sell-HemoCue-business-for-24300-million.aspx>.

  • Chicago

    Quest Diagnostics. "Quest Diagnostics signs definitive agreement to sell HemoCue business for $300 million". News-Medical. https://www.news-medical.net/news/20130225/Quest-Diagnostics-signs-definitive-agreement-to-sell-HemoCue-business-for-24300-million.aspx. (accessed November 24, 2020).

  • Harvard

    Quest Diagnostics. 2019. Quest Diagnostics signs definitive agreement to sell HemoCue business for $300 million. News-Medical, viewed 24 November 2020, https://www.news-medical.net/news/20130225/Quest-Diagnostics-signs-definitive-agreement-to-sell-HemoCue-business-for-24300-million.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Majority of American adults use prescription drugs inappropriately and dangerously